Abstract:BACKGROUND:In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement characterizes a subgroup of patients who show sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, the prognoses of these patients are heterogeneous. A better understanding of the genomic alterations occurring in these tumors could explain the prognostic heterogeneity observed in these patients.METHODS:We retrospectively analyzed 96 patients with NSCLC with ALK detected by immunohistochemical staining (VENTANA anti-ALK(D5F3) Rabbit Monoclonal Primary Antibody). Cancer tissues were subjected to next-generation sequencing using a panel of 520 cancer-related genes. The genomic landscape, distribution of ALK fusion variants, and clinicopathological characteristics of the patients were evaluated. The correlations of genomic alterations with clinical outcomes were also assessed.RESULTS:Among the 96 patients with immunohistochemically identified ALK fusions, 80 (83%) were confirmed by next-generation sequencing. TP53 mutation was the most commonly co-occurring mutation with ALK rearrangement. Concomitant driver mutations [2 Kirsten rat sarcoma viral oncogene homolog (KRAS) G12, 1 epidermal growth factor receptor (EGFR) 19del, and 1 MET exon 14 skipping] were also observed in 4 adenocarcinomas. Echinoderm microtubule associated protein-like 4 (EML4)-ALK fusions were identified in 95% of ALK-rearranged patients, with 16.2% of them also harboring additional non-EML4-ALK fusions. Nineteen non-EML4 translocation partners were also discovered, including 10 novel ones. Survival analyses revealed that patients concurrently harboring PIK3R2 alterations showed a trend toward shorter progression-free survival (6 vs. 13 months, P=0.064) and significantly shorter overall survival (11 vs. 32 months, P=0.004) than did PIK3R2-wild-type patients. Patients with concomitant alterations in PI3K the signaling pathway also had a shorter median overall survival than those without such alterations (23 vs. 32 months, P=0.014), whereas progression-free survival did not differ significantly.CONCLUSIONS:The spectrum of ALK-fusion variants and the landscape of concomitant genomic alterations were delineated in 96 NSCLC patients. Our study also demonstrated the prognostic value of concomitant alterations in crizotinib-treated patients, which could facilitate improved stratification of ALK-rearranged NSCLC patients in the selection of candidates who could optimally benefit from therapy.

Concordance of Immunohistochemistry and Fluorescent in Situ Hybridization for Anaplastic Lymphoma Kinase (alk) Rearrangement in Non-Small Cell Lung Cancer: Results from A Multicenter Study in China

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

Evaluation Of Alk Rearrangement In Chinese Non-Small Cell Lung Cancer Using Fish, Immunohistochemistry, And Real-Time Quantitative Rt- Pcr On Paraffin-Embedded Tissues

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

Comparing Four Different ALK Antibodies with Manual Immunohistochemistry (IHC) to Screen for ALK-rearranged Non-Small Cell Lung Cancer (NSCLC).

A Survival Comparison Study of Chinese Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements with Crizotinib Treatment Detected by FISH, IHC, and RT-PCR.

Comparative study of ALK antibody with manual and automatic immunohistochemical detec-tion in non-small cell lung cancer

A comparative analysis of immunohistochemistry and fluorescent in situ hybridization assay to detect anaplastic lymphoma kinase status in lung adenocarcinoma cases: A search for a testing algorithm

Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS

Alk-Rearranged Lung Cancer In Chinese: A Comprehensive Assessment Of Clinicopathology, Ihc, Fish And Rt-Pcr

Exploration of ALK fused gene expression in non-small cell lung cancer patients by immuno-histochemistry

Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.

Comparison of ALK Detection by FISH, IHC and NGS to Predict Benefit from Crizotinib in Advanced Non-Small-cell Lung Cancer.

Detection of ALK protein in lung squamous cell carcinoma with immunohistochemistry and FISH

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib

Significance and Evaluation of Anaplastic Lymphoma Kinase by Immunohistochemistry in Non-Small Cell Lung Cancer.

Comparison of ALK Status Between Primary and Corresponding Lymph Node Metastatic Tumors in Lung Cancer Patients

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy.

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

[3H]ethynylbicycloorthobenzoate ([3H]EBOB) Binding in Recombinant GABAA Receptors.